Fluomizin 10 mg vaginal tablets

Summary of Product Characteristics Updated 12-Oct-2022 | Gedeon Richter (UK) Ltd

1. Name of the medicinal product

Fluomizin 10 mg vaginal tablets

2. Qualitative and quantitative composition

Each vaginal tablet contains 10 mg dequalinium chloride.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Vaginal tablet

The vaginal tablets are white or almost white, oval and biconvex with approximate dimension of length: 19 mm, width: 12 mm, and thickness: 6.3 mm.

4. Clinical particulars
4.1 Therapeutic indications

Fluomizin 10 mg vaginal tablets are indicated for the treatment of Bacterial vaginosis (see section 4.4)

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration


One vaginal tablet daily for six days.

The vaginal tablets should be inserted deeply into the vagina in the evenings before retiring. This is best performed in a reclining position with the legs slightly bent.

The treatment should be interrupted during menstruation and resumed afterwards.

Although relief of discharge and inflammation generally occurs within 24 to 72 hours, the treatment should be continued even when there is no subjective discomfort (itching, discharge, smell) anymore. A treatment less than six days could result in a relapse.

Fluomizin contains excipients which do not dissolve completely, such that remains of the tablet are occasionally found in the underwear. This is of no importance for the efficacy of Fluomizin.

In rare cases of a very dry vagina, it is possible that the vaginal tablet does not dissolve and is discharged by the vagina as intact tablet. As consequence, the treatment is not optimal. For prevention, the vaginal tablet can be moistened with a drop of water before insertion into a very dry vagina.

Patients should use a sanitary towel or panty liner. There is no change in colour of the underwear.

Women more than 55 years and elderly

There is a lack of data on the efficacy and safety of dequalinium chloride in women above 55 years of age.

Paediatric population

There is a lack of data on the efficacy and safety of dequalinium chloride in children below 18.

Method of administration

For vaginal use

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Ulceration of the vaginal epithelium and the vaginal portion of the cervix.

Young girls who have not yet had their first menstruation, and thus did not reach sexual maturity must not use Fluomizin.

4.4 Special warnings and precautions for use

To minimise exposure of the newborn to dequalinium chloride, vaginal tablets should not be used within 12 hours before birth.

There are no efficacy and safety data available on the re-treatment of patients who did not respond to or relapsed immediately after initial therapy with Fluomizin. Patients should be advised to consult their physician if the symptoms persist at the end of the treatment or in case of recurrence.

Using a higher daily dose or increasing the recommended treatment duration might increase the risk of vaginal ulcerations.

No efficacy and safety data on the treatment of bacterial vaginosis in women aged less than 18 years or more than 55 years are available.

4.5 Interaction with other medicinal products and other forms of interaction

Anionic substances such as soaps, detergents and surfactants can reduce the antimicrobial activity of dequalinium chloride. Thus, concomitant intravaginal use of soaps, spermicides or vaginal douches (vaginal washes) is not recommended.

Fluomizin 10 mg vaginal tablets do not impair the functionality of latex condoms. There are no data on the interaction with non-latex condoms and other intravaginal devices such as diaphragms. Thus, concomitant use of non-latex condoms and other intravaginal devices is not recommended for at least 12 hours following the treatment.

4.6 Fertility, pregnancy and lactation


Limited data from four clinical studies in 181 pregnant patients did not suggest adverse effects on the pregnancy or on the foetus / neonate.

No reproductive toxicity studies have been conducted in animals because of the expected low systemic exposure to dequalinium chloride after vaginal administration.

Fluomizin should only be used in pregnancy if clearly necessary.


Systemic exposure of the breast-feeding women to Fluomizin is negligible. Therefore, no harmful effects on the breastfed newborn/infant are anticipated.

Fluomizin can be used during lactation if clinically needed.

To minimise exposure of the newborn to dequalinium chloride, vaginal tablets should not be used within 12 hours before birth.


No studies on effects on fertility have been conducted in animals.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

4.8 Undesirable effects

In clinical trials, the following undesirable effects possibly or probably related to dequalinum chloride have been reported.

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

System Organ Class


(≥ 1/100 to <1/10)


(≥ 1/1,000 to <1/100)

Not known (cannot be estimated from the available data)

Infections and infestations

• vaginal candidiasis

• bacterial vaginitis,

• fungal skin infection,

• vulvitis,

• vulvovaginitis

• cystitis

Nervous system disorder

• headache

Gastrointestinal disorders

• nausea

Reproductive system and breast disorders

• vaginal discharge,

• vulvovaginal pruritus,

• vulvovaginal burning sensation

• vaginal haemorrhage,

• vaginal pain

• ulceration and maceration of vaginal epithelium,

• uterine bleeding,

• redness,

• vaginal dryness

General disorders and administration site conditions

• allergic reactions with symptoms like urticarial, erythema, exanthema, swelling, rash or pruritus

• fever

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard.

4.9 Overdose

No case of overdose has been reported. However, use of a higher daily dose might result in vaginal ulcerations. In case of overdose with adverse events, a vaginal lavage can be performed.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Gynaecological anti-infective and antiseptic, Quinoline derivatives

ATC code: G01A C05

Dequalinum chloride is an anti-infective and antiseptic agent belonging to the class of quaternary ammonium compounds.

Mechanism of Action

Dequalinium chloride is a surface-active substance. The primary mechanism of action is an increase in bacterial cell permeability and the subsequent loss of enzyme activity, finally resulting in cell death.

Dequalinium chloride exhibits a rapid bactericidal activity.

Dequalinium chloride in vaginal tablets exerts its action locally within the vagina.

Pharmacokinetic/pharmacodynamics relationship

No major PK/PD determinant of efficacy has been established for Fluomizin. As the bactericidal effect of dequalinium chloride occurs within 30 to 60 minutes, the maximum local concentration within the first hour after application is considered crucial for the efficacy.

Mechanism(s) of resistance

The mechanisms resulting in the inherent resistance of some pathogens are not known. No mechanisms of acquired resistance have been observed thus far.


No Breakpoints for dequalinium chloride are available by any recommending body and no relationship between minimal inhibitory concentrations and the clinical efficacy has been established. Thus, the information on susceptibility in the table below is descriptive and is based on the concentrations achievable in the vagina (see section 5.2) and respective MIC data of the pathogens.

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infection is questionable.

Commonly susceptible species

Aerobic Gram-positive bacteria

Enterococcus faecalis

Lactobacillus spp.

Staphylococcus aureus

Streptococcus agalactiae (Group B streptococci)

Streptococcus pyogenes (Group A streptococci)

Aerobic Gram-negative bacteria

Enterobacter spp.

Escherichia coli

Klebsiella spp.

Pseudomonas spp.

Serratia spp.

Anaerobic bacteria

Atopobium vaginae

Bacteroides spp.


Gardnerella vaginalis

Prevotella spp.


Poryphyromonas spp

Species for which acquired resistance may be a problem

None known

Inheritantly resistant organisms

Gram-negative bacteria

Proteus sp.

Chlamydia trachomatis

Other micro-organisms

Trichomonas vaginalis

5.2 Pharmacokinetic properties

After dissolution of a Fluomizin vaginal tablet (10 mg dequalinium chloride) in an estimated 2.5 to 5 ml of vaginal fluid, the dequalinium chloride concentration in the vaginal fluid is 2000 - 4000 mg/l.

Preclinical data indicate that dequalinium chloride is absorbed only to a very small amount after vaginal application.

Therefore, systemic exposure to Fluomizin is negligible and not further pharmacokinetic data are available.

5.3 Preclinical safety data

Systemic toxic effects of Fluomizin are unlikely on the basis of the negligible systemic exposure of dequalinium chloride administered intravaginally.

In vivo and in vitro studies with dequalinium chloride did not yield any indication of a potential to cause mutagenicity.

No reproduction toxicity studies have been conducted with dequalinium chloride.

A study in rabbits showed the good vaginal tolerance of Fluomizin.

6. Pharmaceutical particulars
6.1 List of excipients

Lactose monohydrate

Cellulose, microcrystalline

Magnesium stearate

6.2 Incompatibilities

Fluomizin is incompatible with soaps and other anionic surfactants.

6.3 Shelf life

3 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

PVC/PE/PVdC/aluminium blisters

Packs of 6 vaginal tablets

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Kora Corporation Ltd. t/a Kora Healthcare,

20 Harcourt Street,

Dublin 2,

D02 H364


8. Marketing authorisation number(s)

PL 39972/0004

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text
Company Contact Details
Gedeon Richter (UK) Ltd

127 Shirland Road, London, W9 2EP, UK

Medical Information Fax




+44(0)207 604 8800

Medical Information Direct Line

+44 (0)207 604 8806

Customer Care direct line

+44 (0)207 604 8800

Medical Information e-mail